Gb Sciences uses AI to create new cannabis-inspired anti-inflammatories

202 0

The cannabis company is making strides in developing safer medical marijuana products

Artificial intelligence (AI) has started to be implemented in many industries in order to optimize many of their internal processes. The cannabis sector has been no stranger to this revolutionary technology. Now, Gb Sciences is leveraging a proprietary AI-enabled drug discovery platform to identify new cannabis-inspired mixtures as anti-inflammatory therapies. The leading plant-inspired biopharmaceutical research and development company wants to continue to create new solutions in this growing medical cannabis industry.

Gb Sciences is developing cannabis-inspired anti-inflammatory therapies to combat cytokine release syndrome (CRS). This solution targets dangerous hyper-inflammatory responses to viral infections, such as COVID-19 and others. The huge wave of infection caused by the coronavirus worldwide inspired this firm to create anti-inflammatory drugs designed to treat future viral outbreaks and part of their answer was found through the effects of cannabis.

Approximately seven months ago, Gb Sciences announced that a draft clinical trial protocol would be written for a first-in-human trial of these proprietary cannabinoid-based formulations. Gb Sciences’ CRS therapy stands apart from the rest thanks to its preventative opportunities and seasonal intervention for patients when they discover they have been exposed to a certain hyperinflammation-causing virus.

The treatment can also be effective for those who are experiencing CRS symptoms as a side effect of certain new cancer therapies. Gb Sciences used PhAROS, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures. The results were able to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses.